CD30 Ligand/TNFSF8 蛋白, Human (HEK293)

CD30 Ligand is a B cell surface antigen and a ligand for CD30 (TNFRSF8), playing an inhibitory role in CD40-mediated immunoglobulin class switching^[1]. CD30 Ligand is also a a marker for Hodgkin lymphoma and related hematologic malignancies, involves in activation and functioning of the T cell-dependent immune system^[2]. CD30 ligand is expressed by T and B lymphocytes, macrophages, and a variety of normal haematopoietic cells and derived tumours. CD30 ligand exerts pleiotropic effects on normal and malignant lymphoid cells, including death, differentiation, or cell division^[3]. As for CD30 ligand in human is a type II membrane-associated glycoprotein belonging to the tumor necrosis factor (TNF) family. CD30 Ligand/TNFSF8 Protein, Human (HEK293) is 172 amino acids in length (Q63-D234) and is expressed in the HEK293 cells with tag free.

CD30 配体 (CD30L) 是一种 B 细胞表面抗原，也是 CD30 (TNFRSF8) 的配体，在 CD40 介导的免疫球蛋白类别转换中发挥抑制作用^[1]。
CD30L 是一种类型II 膜相关糖蛋白，属于肿瘤坏死因子 (TNF) 家族，结构上与肿瘤坏死超家族成员 TNF α、TNF β 和 CD40 相关^[1][3]。
CD30L可增强某些淋巴瘤细胞系的细胞增殖，同时诱导其他淋巴瘤细胞系的细胞死亡并减少细胞增殖，从而在霍奇金和某些非霍奇金淋巴瘤中发挥病理生理作用。CD30L 还可增强细胞因子 IL-6、TNF、LT-a^[2] 的释放。
CD30L 对正常和恶性淋巴细胞发挥多效作用，包括死亡、分化或细胞分裂调节^[3]。
CD30L主要表达于活化的T细胞、B细胞、巨噬细胞和DC上，而CD30/CD30L主要表达于固有层活化的CD4+T细胞表面（ LP），尤其是在 Th17 细胞分化的早期阶段。CD30L 缺乏可抑制肠粘膜中 Th17 细胞的分化和 IL-17A 的产生^[4]。
CD30L 作为促炎细胞因子，参与溃疡性结肠炎的适应性免疫反应结肠炎（UC），其水平与UC的严重程度呈正相关^[5]。

Human

HEK293

Tag Free

P32971 (Q63-D234)

944  [NCBI]

Approximately 19.6 kDa.

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.

• [1]. Cerutti A, et al. CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. Immunity. 1998 Aug;9(2):247-56.  [Content Brief]

  [2]. Gruss H-J, et al. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Leuk Lymphoma. 1996 Feb;20(5-6):397-409.  [Content Brief]

  [3]. Pera MF, et al. CD30 and its ligand: possible role in regulation of teratoma stem cells. APMIS. 1998 Jan;106(1):169-72; discussion 173.  [Content Brief]

  [4]. Wang X, et al. CD30L/CD30 signaling regulates the formation of the tumor immune microenvironment and inhibits intestinal tumor development of colitis-associated colon cancer in mice. Int Immunopharmacol. 2020 Jul;84:106531.  [Content Brief]

  [5]. Mei C, et al. CD30L+ classical monocytes play a pro-inflammatory role in the development of ulcerative colitis in patients. Mol Immunol. 2021 Oct;138:10-19.  [Content Brief]